Vanda Pharmaceuticals INC.
Forward trial catalysts linked to VNDA
CSA tracks 1 forward catalyst for Vanda Pharmaceuticals INC. across 1 asset, spanning Phase 3. The nearest is a readout expected Dec 1, 2026 (day precision). Confidence across its tracked catalysts breaks down as 1 medium. Tracked indications include Nausea and Vomiting.
VNDA in the full snapshot
The free sample on this page is a slice. In the current full CSA snapshot, Vanda Pharmaceuticals INC. has:
Forward catalysts by year
Every catalyst in the snapshot comes with its date, date confidence and source link.
1 trial behind these assets
| Asset | Trial | Phase | Status | Primary completion | Role | Lead sponsor | Condition(s) |
|---|---|---|---|---|---|---|---|
| tradipitant | NCT07446439 catalyst | Phase 3 | Recruiting | 2026-12-01 | Experimental | Vanda Pharmaceuticals | Nausea and Vomiting; Obesity |
Every trial the CSA sample links to VNDA's tracked assets.
Conditions studied
Data, not investment advice. CSA is information, not a recommendation to buy, sell or hold any security. Estimated catalyst dates routinely slip and are graded by confidence — verify against the source link before acting.
This sponsor's catalysts are a slice of the free CSA sample. The full snapshot covers active, industry-sponsored Phase 3 trials in cardiometabolic, oncology and immunology. Every forward catalyst carries its date, confidence grade and source link, and is linked to its sponsor's ticker when the sponsor is a listed company.
Get the full dataset — $499 →